Highlights Daiichi Sankyo Company, Limited

Equities

4568

JP3475350009

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 06:30:00 13/02/2026 GMT			5-day change	1st Jan Change
2,937.50 ^JPY	+1.08%		+2.39%	-12.26%

02-03	AstraZeneca Says Breast Cancer Treatment Granted US FDA Priority Review	MT
02-03	Daiichi Sankyo And AstraZeneca Receive Priority Review For DATROWAY For Treatment Of Unresectable Or Metastatic Triple Negative Breast Cancer In The U.S	CI

Highlights

02-03	Daiichi Sankyo And AstraZeneca Receive Priority Review For DATROWAY For Treatment Of Unresectable Or Metastatic Triple Negative Breast Cancer In The U.S	CI
01-30	Daiichi Sankyo's Nine-Month Profit Rises 4%	MT
01-30	Daiichi Sankyo Company, Limited Reports Earnings Results for the Nine Months Ended December 31, 2025	CI
01-28	Berenberg Ups AstraZeneca Price Target on Datroway's Sales Potential in Lung Cancer	MT
01-19	Daiichi Sankyo and AstraZeneca cheer EU milestone for cancer drug	AN
01-19	European Medicines Agency Validated in the EU as First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer	CI
01-07	Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for Nanflyta®? Commercialization in Central and Eastern Europe	CI
01-05	Tranche Update on Daiichi Sankyo Company, Limited's Equity Buyback Plan announced on April 25, 2025.	CI
12-29	Cardiogeni swings to loss as Daiichi Sankyo deal drops away	AN
12-24	Daiichi Sankyo Announces Approval of ENHERTU® in China as First HER2 Directed Medicine for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following Disease Progression After One or More Endocrine Therapies	CI
12-22	AstraZeneca, Daiichi Sankyo's Breast Cancer Drug Granted Breakthrough Therapy Status in US	MT
12-22	Harbour Energy makes USD3.2 billion US buy	AN
12-22	Enhertu® Granted Breakthrough Therapy Designation in the U.S. as Post-Neoadjuvant Therapy for Patients with Her2 Positive Early Breast Cancer	CI
12-21	Daiichi Sankyo Company, Limited Destiny-Endometrial02 Phase 3 Trial of Enhertu Initiated as Adjuvant Therapy in Patients with Her2 Expressing Endometrial Cancer	CI
12-18	Daiichi Sankyo and AstraZeneca's DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy	CI
12-16	AstraZeneca, Daiichi Sankyo's Enhertu Regimen Greenlit as First-line Breast Cancer Treatment in US	MT
12-16	AstraZeneca, Daiichi Sankyo's Enhertu Combination Gets US Approval for Breast Cancer Treatment	MT
12-15	Roche Receives FDA Approval for First Diagnostic Tests to Identify HER2-Positive Metastatic Breast Cancer Patients Eligible for ENHERTU	CI
12-15	AstraZeneca, Daiichi's breast cancer drug gets FDA nod as first-line treatment	RE
12-15	Lunit Announces Collaboration with Daiichi Sankyo to Advance AI-Driven Biomarker Discovery and Translational Oncology Research	CI
12-03	Federal Circuit Court of Appeals vacates infringement judgment and damages award in dispute between Daiichi Sankyo and Seagen	RE
12-03	Daiichi Sankyo Co Ltd - Federal Circuit Court of Appeals Vacates Infringement Judgment and Damages Award in Dispute Between Daiichi Sankyo and Seagen	RE
11-12	General Proximity Announces A Strategic Multi-Target Collaboration with Daiichi Sankyo	CI
11-10	Daiichi Sankyo Announces Dosed in First-In-Human Phase 1 Trial Evaluating Ds3610 in Patients with Advanced Solid Tumors	CI
31/10/25	Daiichi Sankyo's Attributable Profit Slides 11% in Fiscal H1	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Highlights Daiichi Sankyo Company, Limited

Equities

4568

JP3475350009

Pharmaceuticals

Highlights

Filters